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Abstract 
Stabilized microbubbles with a size between 1-5 µm are used as ultrasound contrast agents in 
the clinical routine. They have shown convincing results for the vascular characterization of 
tissues as well as in echocardiography. Due to their size, microbubbles strictly remain in-
travascular where they can be detected with high sensitivity and specificity. This qualifies them 
for intravascular molecular imaging. Many studies have been published reporting on the 
successful use of microbubbles conjugated to specific ligands for target identification in vivo. 
Among them, there are several promising examples on how to use molecular ultrasound for 
the imaging of integrin expression. This review provides an overview on the composition of 
ultrasound contrast agents that can be used for molecular imaging and their detection by 
ultrasound using destructive and non destructive methods. Furthermore, concrete examples 
are given on the use of molecular ultrasound to characterize integrin expression on vessels. 
These cover oncological applications where integrin targeted microbubbles were used to 
identify and characterize tumor angiogenesis and to assess tumor response to antiangiogenic 
drugs as well as to radiotherapy. In addition, increased accumulation of integrin targeted 
microbubbles was found during vascular reformation in ischemic tissues as well as in vul-
nerable atherosclerotic plaques. In summary, there is clear evidence from preclinical studies 
that integrin targeted ultrasound imaging is a valuable tool for the characterization of a broad 
spectrum  of  diseases.  Thus,  more  efforts  should  be  put  into  translating  this  promising 
technology into the clinics. 
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1. The role of ultrasound in tumor imaging 
In the clinical routine ultrasound often is the first 
imaging modality applied to patients. Reasons are its 
low costs, the high mobility and the lack of exposure 
of the patient to radioactive radiation. Furthermore, 
ultrasound  is  a  real  time  imaging  modality,  which 
further makes this imaging tool suitable for interven-
tional procedures (e.g. biopsy). 
Besides  providing  anatomical  information  ul-
trasound is capable of displaying  the perfused vas-
culature and allows deriving functional vascular pa-
rameters – even without the need of injecting contrast 
material. Non contrast enhanced vascular imaging is 
based  on  the  Doppler  principle,  which  is  also  im-
portant  for  targeted  ultrasound.  In  ultrasound  the 
Doppler  Effect  describes  the  frequency  shift  of  an 
acoustic wave by its reflection from a moving element 
[1]. If the object is moving towards to the transducer, 
the frequency increases and if it moves away, it de-
creases.  In  blood  vessels  acoustic  pulse  waves  are 
mainly scattered by blood cells, which form the major Theranostics 2011, 1 
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blood cell fraction. The frequency shifts can be color 
coded and overlaid with the morphologic ultrasound 
images to visualize vessels and their flow velocities. 
Unfortunately, micro vessels with very slow flow ve-
locities of blood cells can not be detected. Here ultra-
sound  contrast  agents  can  be  used  and  these  have 
proven to be valuable tools to detect angiogenic tu-
mors and to characterize liver lesions by its vascular-
ization [2]. 
Nevertheless, a local increase in vascularization 
can have many reasons reaching from cancer to au-
toimmunological  and  infectious  disorders.  Further-
more, the clearance time of ultrasound contrast agents 
from the blood is fast and thus labeling of these le-
sions  persists  only  for  a  short  period  of  time.  This 
complicates the use of contrast agents during inter-
ventions.  Thus,  the  availability  of  molecular  ultra-
sound contrast agents providing longer local contrast 
and  giving  more  information  about  the  molecular 
background of the lesion are of high clinical interest. 
In this context, integrins have proven to be excellent 
markers of angiogenic vessels and their downregula-
tion during anti-angiogenic therapies seems to indi-
cate therapy response reliably. Therefore, ultrasound 
contrast agents targeting integrins can be considered 
to  be  exquisite  tools  to  characterize  angiogenic  le-
sions, to demarcate these lesions during image guided 
interventions  and  to  track  pharmacological  tumor 
therapy response [3, 4].  
There are several reasons why these targeted ul-
trasound  contrast  agents  are  not  in  the  clinics  yet: 
First, the development costs for diagnostic agents are 
high  and  the  more  specific  a  contrast  agent  is,  the 
smaller  is  the  market.  Therefore,  pharmaceutical 
companies are cautious to develop such products for 
the clinics. 
Second, ultrasound is user dependent and thus 
reproducibility  of  measurements  is  limited.  Fortu-
nately,  novel  automated  3D  acquisition  techniques 
have been introduced in the clinics by several com-
panies  recently,  which  certainly  will  have  positive 
impact on the establishment of targeted ultrasound.  
Third, there is some competition with other mo-
lecular imaging modalities (such as positron emission 
tomography).  Personally,  we  do  not  consider  this 
conflict to be relevant since ultrasound fills niches in 
real time imaging, bedside imaging and intervention-
al imaging, while most other imaging modalities have 
their strengths in whole body imaging.  
Additionally, there are concerns about the safety 
of  ultrasound  contrast  agents.  Indeed,  there  are  re-
ports on immunological reactions and even on lethal 
complications after the administration of ultrasound 
contrast agents in patients with severe cardiac disor-
ders.  However,  a  causal  connection  between  these 
deaths and the administration of ultrasound contrast 
agents  has  not  been  proven,  yet.  Furthermore,  im-
munological  reactions  appear  much  less  often  after 
injection of ultrasound contrast agents than after in-
jection  of  X-ray  or  MRI  contrast  agents.  Therefore, 
although  ultrasound  contrast  agents  can  be  consid-
ered to be relatively save, one has to keep in mind that 
all administered drugs can have side effects and that 
the indication for their application should always be 
made thoughtfully. 
2. Microbubbles as contrast agents 
On ultrasound images the contrast depends on 
absorption, reflection and scattering of the ultrasound 
pulse  by  tissue  elements.  An  ultrasound  contrast 
agent thus has to be a stronger acoustic reflector than 
the environment or even act as an acoustic emitter. It 
may also change the spectrum of the ultrasound pulse 
(non linear reflection) and thus generate its own spe-
cific fingerprint.  
In general, molecules that reflect the ultrasound 
pulse linearly can be nano- to micrometer scaled and 
acoustically  will  behave  similar  to  erythrocytes. 
However, they can not be detected with high sensi-
tivity and specificity.  
In contrast, taking into account the frequencies in 
which clinical ultrasound operates (2-20 MHz) a mi-
crobubble of 1-3 µm in diameter can be optimally ex-
cited (and / or even destroyed) by ultrasound pulses 
and thus will provide a much stronger signal. Cur-
rently all commercial ultrasound contrast agents con-
sist of stabilized microbubbles [5].  
Ultrasound contrast agents can be classified ac-
cording  to  the  rigidity  of  their  shell.  Soft-shell  mi-
crobubbles have either no coating or are covered by a 
thin monolayer of surfactant molecules such as pal-
mitic acid or phospholipids and are very sensitive to 
pressure  changes.  Hard-shell  microbubbles  have  a 
more  rigid  shell  made  of  polymers  or  denaturized 
albumin, which can increase their stability to a certain 
degree. Both microbubble  classes can be filled  with 
either air or heavy gases such as sulfohexafluoride or 
perfluorocarbon. The advantage of heavy gases is the 
longer lasting stability of the gas bubble in the blood 
and the longer blood half life of the ultrasound con-
trast agent in the body. This is particularly important 
for soft shell bubbles, which are more vulnerable than 
hard shell bubbles. Thus most of them contain heavy 
gases. An overview on the commercially developed 
microbubbles  and  its  characteristics  is  given  in       
Table  1,  which  was  taken  from  a  publication  of 
Kiessling and colleagues [5]. Theranostics 2011, 1 
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Table 1. Overview on ultrasound contrast agents, which were developed in respect of a clinical application [5].  
 
 
 
 
 
The  design  of  targeted  ultrasound  contrast 
agents is not significantly different from these regular, 
non-specific  perfusion  agents,  however,  two  major 
additional requirements have to be considered: 
1.  Attachment of specific ligands to the sur-
face of the microbubble surface has to be possible.  
2.  The blood half life of the microbubble must 
be long enough to enable binding and accumulation 
at the target. Furthermore, the target persistence time 
has  to  be  long  enough  to  generate  a  suitable  time 
window for its detection. 
For the coupling of binding moieties amino- or 
carboxylic  groups  should  be  available  at  the  mi-
crobubble surface. These can be used to couple strep-
tavidin or biotin. Since biotin binds to streptavidin in 
a non covalent but very stable manner, biotinylated 
antibodies or peptides can then be linked to the mi-
crobubble (Fig. 1). This conjugation route is chosen by 
most groups working on targeted ultrasound. How-
ever, from the clinical perspective this concept is not 
translatable  since  streptavidin  is  immunogenic  in 
humans. As a consequence for the clinical application 
alternative conjugation routes have to be used. Direct 
coupling  of  ligands  can  be  performed  but  often  is 
complex  from  the  chemical  point  of  view. 
Poly-ethylene-glycol  (PEG)  can  facilitate  coupling, 
increase hydrophilicity and improve the target affin-
ity of the molecular microbubble. Alternatively click 
chemistry can be used. This has the advantage of fa-
cilitating the use of different ligands without the need 
for time consuming individual optimization of cou-
pling strategies.    
A broad variety of different ligands can be cou-
pled  to  microbubbles  reaching  from  antibodies  and 
their  fragments  to  small  peptides,  peptidomimetics, 
aptamers and lectines. With respect to integrins tar-
geting  cyclic  RGD  peptides  and  αvβ3-binding  anti-
bodies have been used so far (specified below). 
 
 
 
Name  Manufacture  Gas core  Shell composition 
Imagify
TM  Acusphere  Decafluorobutane  poly-L-lactide co-glycide 
Albunex
®  Mallinckrodt  Air  Albumin 
BiSphere
TM  Point Biomedical  Air  Polymer/Bilayer 
BR14
®  Bracco  Perfluorocarbon  Phospholipid 
BY963  Nycomed  Air  Lipid 
Cardiosphere  Point Biomedical  Nitrogen  Polylactid/Albumin 
Definity
®  DuPont/BMS  Octafluoropropane  Liposome 
Echogen  Sonus  Dodecafluoropentane  Surfactant 
Echovist
®  Schering  Air  No shell (galactose matrix) 
Imagent
®  IMCOR  Perfluorohexane  Surfactant 
Levovist
®  Schering  Air  Palmitic acid 
MP1950  Mallinckrodt  Perfluorobutane  Phospholipid 
Myomap  Quadrant  Air  Albumin 
Optison
®  GE Healthcare  Octafluoropropane  Albumin 
PESDA  Porter  (Univ.  of 
Nebraska) 
Perfluorocarbon  Albumin 
Quantison
TM  Quadrant  Air  Albumin 
Sonavist  Schering  Air  Polycyanoacrylate 
Sonazoid
TM  GE Healthcare  Perfluorocarbon  Lipid 
Sonovue
®  Bracco  Sulphur hexafluoride  Phospholipid Theranostics 2011, 1 
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Figure 1. Synthesis of target specific ultrasound contrast agents. 
 
 
3.  Detection techniques 
Stationary microbubbles can be detected by dif-
ferent strategies: The simplest approach is to measure 
the  relative  contrast  enhancement  within  a 
two-dimensional  ultrasound  image  after  the  freely 
circulating microbubbles have been cleared from the 
blood (which usually takes few minutes) (Fig. 2).  
Alternatively,  the  subharmonic  and  harmonic 
echoes can be used to detect microbubbles by their 
specific fingerprints. Even pulse inversion techniques 
can be applied, which effectively suppress the tissue 
background [5]. These approaches work most favora-
bly at low mechanical indexes – meaning at low ul-
trasound pulse energy, which is sufficient to excite the 
microbubble without destroying it.   
If  high  acoustic  pressures  are  applied  the  mi-
crobubble disintegrates, which is termed “destructive 
imaging”.  During  microbubble  destruction,  the  air 
rapidly  streams  out  of  the  collapsing  microbubble 
shell, which generates a strong non linear signal. This 
signal can be detected by Doppler and is determined 
“Loss of Correlation”. Since thereby every microbub-
ble will only be counted once, exquisite options for the 
quantification of the microbubble concentration in the 
tissue  are  given.  Unfortunately,  the  thickness  of  an 
ultrasound  slice  is  depth    dependent  and  certainly 
larger  than  the  diameter  of  one  microbubble.  Also 
from the echo  characteristics it is difficult to distin-
guish  whether  the  signal  within  a  voxel  originates 
from only one or from several microbubbles. Satura-
tion of the Doppler-signal is reached rapidly, which 
complicates quantification of stationary microbubble 
concentrations.  Reinhardt  and  coworkers  partially 
solved this problem by using a novel method deter-
mined as “Sensitive Particle Acoustic Quantification 
(SPAQ)”  [6]  (Fig.  3).  SPAQ  is  a  3-dimensional  scan 
procedure with overlapping image slice acquisitions. 
For this purpose the scanned object or the transducer 
are coupled to a servo-motor and moved in microm-
eter  steps  during  image  acquisition.  An  ultrasound 
energy pulse capable of destroying the microbubbles 
is  applied.  During  the  first  destructive  image  mi-
crobubbles burst in a broad slice and quantification is 
difficult.  However,  after  a  micrometer  scaled  shift 
between  the  object  and  the  transducer  new  mi-
crobubbles  will  only  be  destroyed  in  the 
non-overlapping distance. Thus, the next and also all 
subsequent  ultrasound  scans  will  only  capture  mi-
crobubbles from very thin excitation slices in which 
single microbubbles are detected.  
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Figure 2. Non-destructive two-dimensional technique to assess the accumulation of targeted microbubbles. 
 
 
 
Figure 3. Three-dimensional quantification of stationary contrast agents using the sensitive particle acoustic quantification 
technology (SPAQ [6]). Drawings illustrate the principle of SPAQ. If an ultrasound transducer moves over an object (here: 
Agar-phantom containing microbubbles), the ultrasound beam destroys the microbubbles within the acoustic field. (A) Low 
frame-to-frame displacement between the single ultrasound pulses results in a high SPAQ resolution providing good dis-
crimination of single signals. (B and C) Higher displacements (= larger SPAQ-slices) produce lower SPAQ resolutions finally 
resulting in an overlay of single SAE signals. “Proof-of-principle” in an agar phantom filled with microbubbles. Adapted from 
reference 16 with permission.  
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4. Applications 
αvβ3 integrin  has been intensively studied as a 
target for imaging inflammation or tumor angiogene-
sis. Like VEGFR2, αvβ3 integrin  is highly expressed 
on activated endothelium and almost absent on the 
remaining vessels [7]. Thus, it is an ideal target for the 
diagnosis  of  vessels  activated  by  inflammation  or 
tumor  angiogenesis.  However,  when  using  ultra-
sound contrast agents it is important to note that ul-
trasound contrast agents  remain within the vessels, 
due to their  size in the range of micrometers. There-
fore, only targets expressed by endothelial cells can be 
addressed.  Different  binding  ligands  have  been  ex-
plored for targeting αvβ3  integrin, as summarized in 
Table 2.  
 
Table 2. Overview on studies about molecular ultrasound imaging of integrins 
 
 
 
 
 
Leong-Poi and colleagues used monoclonal an-
tibodies  against  murine  αv  or  echistatin,  a  viper 
venom  disintegrin  containing  the  well  known  RGD 
(arginine–glycine–aspartic  acid)  sequence  [8].  Anti-
body-bearing and echistatin-conjugated microbubbles 
exhibited high potential to image activated endothe-
lium  in  subcutaneously  implanted  Matrigel  plugs 
enriched with fibroblast growth factor-2 (FGF-2). Mi-
crobubble retention inside the microvasculature was 
much higher as compared to non-targeted microbub-
bles, however, no significant differences in the reten-
tion of both types of targeted microbubbles were ob-
served. Thus, monoclonal antibodies against murine 
αv and echistatin can be used for targeted imaging 
approaches. 
In another study, Leong-Poi and colleagues ap-
plied  echistatin-conjugated  microbubbles  to  assess 
endogeneous  and  therapeutic  arteriogenesis  in  a 
hindlimb ischemia model in rats [9]. They observed an 
increase in retention of integrin-binding microbubbles 
prior  to  a  measurable  increase  in  blood  flow.  The 
binding of targeted microbubbles was even greater in 
a  treatment  group  (FGF-2  therapy).  These  results 
demonstrate  the  high  potential  of  molecular  ultra-
sound imaging to elucidate regulatory mechanisms, 
preceding the structural changes assessable by func-
tional imaging techniques (e.g. increased blood flow 
due to new vessels).  
Echistatin was further used as a binding ligand 
to image αvβ3 expression in human glioma cells im-
planted intracerebrally in rats [10]. In this study, the 
authors were able to demonstrate significant retention 
of  targeted  microbubbles  within  tumors,  and  also 
reported on increasing accumulation after 14 days of 
tumor growth. They correlated the changing marker 
expression to changes in blood volume and were the 
first  to  state  that  imaging  should  be  performed  in 
combination  with  assessment  of  microbubble  reten-
tion and relative blood volume. Assessing both types 
of information permits a conclusion to be drawn as to 
whether  the  changing  retention  of  microbubbles  is 
related to a general change in the endothelial surface 
(e.g. relative blood volume) or to a real up- (or down-) 
regulation of the markers by the endothelial cells. 
Dayton and coworkers did not use Echistatin but 
cyclic analogs of the RGD ligand as well as integrin 
binding antibodies. Both ligands showed specific ad-
hesion  to  αvβ3-expressing  cell  monolayers  in  vitro 
 
Author  Year  Ligands  Application 
Leong-Poi et al. [8]  2003  Echistatin and  
antibodies  
  Cremaster muscle of mice treated with FGF-2 and 
  s.c. implanted FGF-2 enriched matrigel plugs in mice 
Ellegala et al. [10]  2003  Echistatin    human gliomas orthotopically implanted in rats 
Dayton et al. [11]  2004  cyclic RGD-peptides  
and antibodies 
  Cell monolayers in vitro  
Leong-Poi et al. [9]  2005  Echistatin    Hindlimb  ischemia  in  rats  during  endogeneous  and 
therapeutic arteriogenesis 
Willmann et al. [12]  2008  Antibodies    Cell monolayers  
  human ovarian cancer cells s.c. implanted in mice 
Palmowski et al. [14]  2008  Cyclic RGD-peptides    Human  squamous  cell  carcinomas  in  mice  during 
tumor progression and antiangiogenic treatment 
Palmowski et al. [15]  2009  Cyclic RGD-peptides    Rat  prostate  cancer  s.c.  implanted  in  rats  during 
treatment with charged particles (heavy ions) Theranostics 2011, 1 
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[11]. The idea of using cyclic RGD-peptides and anti-
bodies has then been taken up by Willmann and col-
leagues  who  produced  dual-targeted  microbubbles 
[12]. Their contrast agents were coated by an equal 
amount  of  RGD-peptides  and  antibodies.  They 
showed superior binding properties both in vitro and 
in vivo as compared to microbubbles conjugated ei-
ther  with  antibodies  or  RGD-peptides  alone.  The 
principle  of  an  enhanced  binding  of  microbubbles 
coated with different ligands has been described by 
Rychak et al before [13]. They assumed that fast (but 
unstable) binding peptides enable a firmer binding by 
antibodies.  The  combination  of  antibodies  with  fast 
binding peptides may thus open the door to contrast 
agents  with  superior  specificity  to  selected  targets 
(e.g. integrins). 
Another group investigated the effects of an an-
ti-angiogenic  treatment  on  the  expression  of  αvβ3 
integrins (and VEGFR2) [14]. VEGFR2 antibodies and 
cyclic RGD-peptides served as ligands. They used a 
three-dimensional  imaging  technique  (SPAQ,  [6]), 
enabling  the  sequential  administration  of  different 
batches of specific microbubbles over short time in-
tervals.  Palmowski  and  colleagues  hereby  demon-
strated an upregulation of VEGFR2 and of αvβ3 in-
tegrin during the growth of untreated tumors, and a 
downregulation of both markers after antiangiogenic 
therapy. In a subsequent study, the same group ob-
served  an  upregulation  of  integrin-expression  after 
irradiation with charged particles in prostate tumors 
[15] (Fig. 4). The study was motivated by the upcom-
ing demand for individualized treatments with com-
bination  of  radiotherapy  and  targeted  drugs. 
Knowledge about the behavior of molecular targets 
after irradiation  might enable to define the optimal 
time  points  for  administration  of  individualized 
therapy regimens.  
Molecular  ultrasound  imaging  proved  to  be  a 
reliable tool not only for diagnosis of integrin expres-
sion in suspect tissues but also for assessing changes 
in  the  expression  of  αvβ3  integrin  during  disease 
progression or after different forms of treatment.  
 
 
 
Figure 4. Subcutaneously implanted rat prostate carcinomas seven minutes after administration of unspecific microbubbles 
(left image) and RGD-coated microbubbles (right). Examinations were performed with the destructive imaging technique 
SPAQ [6]. After administration of specific ultrasound contrast agents, a large amout of Doppler signals can be detected 
within the tumor. 
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